Objective:To observe the effect of Xingnaojing injections combined with edaravone in the treatment of acute cerebral hemorrhage. Methods:The patients with acute cerebral hemorrhage were randomly divided into the observation group and the control group with 44 cases in each. The two groups were both given conventional treatment. The control group was treated with 30mg edara-vone injections in 0. 9% 500ml sodium chloride infusions, ivd (infused in 30min), bid, while the observation group was additionally given 10ml Xingnaojing injections in 5. 0% 250ml glucose infusions, ivd, qd. After the 4-week treatment, NIHSS score, GCS score, brain edema and hematoma volume, the levels of high sensitive C reactive protein (hs-CRP) and interleukin-6 (IL-6) before and after the treatment in the two groups were observed and compared, and adverse drug reactions were also recorded. Results: After the treat-ment, GCS score was significantly improved (P<0. 05) and NIHSS score was decreased significantly (P<0. 05) in the two groups, and the observation group was better than the control group (P<0. 05). After the treatment, cerebral edema and hematoma volume was notable reduced in the two groups (P<0. 05), while the difference between the two groups was not statistically significant (P>0. 05). The levels of hs-CRP and IL-6 were decreased significantly after the treatment in the two groups (P<0. 05), and the decrease in the observation group was more significant than that in the control group (P<0. 05). The incidence of adverse reactions in the two groups showed no significant difference (P>0. 05). Conclusion: Compared with edaravone alone, Xingnaojing injections combined with edaravone in the treatment of acute cerebral hemorrhage show more significant efficacy.